Bronchitis

Bronchiolitis

Inflammation of the bronchioles, usually seen in young children, occasionally in high-risk adults. May be seasonal (winter and spring) and often occurs in epidemics.

Aspergillosis

Disease caused by a ubiquitous mold that primarily involves the lungs. Disease frequently lethal in neutropenic and bone marrow transplant (BMT) patients.

Gemifloxacin

Gemifloxacin, as a member of the fluoroquinolone class, acts by inhibiting bacterial topoisomerase IV and DNA gyrase. These enzymes are required for DNA replication, transcription, repair, and recombination.

Acute Exacerbations of Chronic Bronchitis: Emerging therapies

Despite the large patient populations with respiratory tract infections (RTIs), in recent years, many biopharmaceutical companies have shifted development effort away from RTIs to pursue other disease areas with perceived higher unmet need (e.g., resistant hospital-acquired infections). Likewise, many companies have shifted away from antibacterial drug development in favor of chronic disease markets perceived to have higher return on investment.

Ketolides: Cethromycin

Ketolides are a new class of antibacterials specially designed to combat respiratory tract pathogens that have acquired resistance to macrolides. The ketolides are derivatives of the macrolide erythromycin A.

Streptogramins

Streptogramins are produced by streptomycetes and are classified as A or B compounds, based on their mechanism of action as outlined below. As a class, streptogramin A and B compounds are bacteriostatic when used separately.

Peptide Deformylase Inhibitors

Peptide deformylase is an essential bacterial metalloenzyme required for protein synthesis and thus represents a good target for antibacterial therapy. Peptide deformylase inhibitors act on the peptide deformylase enzyme, disrupting protein maturation and inhibiting protein synthesis.

Dihydrofolate Reductase Inhibitors

The dihydrofolate reductase (DHFR) inhibitors target bacterial DHFR, an enzyme involved in the folic acid pathway, thereby disrupting bacterial replication. DHFR inhibitors target both gram-positive and gram negative-bacteria and hence could serve as broad-spectrum antibacterials.

Glycopeptides

Glycopeptides are used for the treatment of severe or life-threatening infections that are caused by gram-positive organisms such as streptococci and staphylococci. In acute exacerbations of chronic bronchitis , they are used rarely.

Tetracyclines

Tetracyclines are the prototypical broad-spectrum antibiotic and are occasionally used as first-line agents in some markets (e.g., Germany) for the treatment of mild acute exacerbations of chronic bronchitis, particularly when cost, penicillin hypersensitivity, and β-lactam resistance are of concern. The widespread use of tetracyclines has resulted in a steady increase in the prevalence of resistance to these agents. Therefore, empiric use of tetracyclines is usually restricted to regions where resistance levels remain low or when other appropriate antibiotics are contraindicated.